About this raise: TrippBio, with a post-money valuation of $7.1 million, is raising funds on NetCapital. The company is developing a new therapeutic application of an FDA-approved drug for the treatment and prevention of the SARS-CoV-2 virus. The company believes that the drug TD213 is capable of preventing the host cell from assembling the virus that causes COVID-19. Billy Meadow and Richard Still founded TrippBio in May 2020. The current round of crowdfunding has a minimum raise of $10,000 and a maximum raise of $1,070,000, and the funds will be used for initial clinical trial, development and manufacturing of TD213, marketing and advertising, professional services, and ramp-up clinical trial. TrippBio is well-positioned to help the world combat COVID-19 and other infectious diseases.
Investment Overview
Invested : $185,796
Deal Terms
Total Commitments ($USD)
- Platform
- Netcapital
- Start Date
- 09/16/2020
- Close Date
- 01/29/2021
$10,000
$1,070,000
$100
Equity - Common
Pre-Seed
RegCF
/ RegD 506(c)
$4.00
$5,255,840
Company & Team
Company
- Year Founded
- 2020
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B
- Margin
- Medium
- Capital Intensity
- High
Team
- Employees
- 18
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
Company Funding & Growth
Funding history
Growth Charts
Revenue History
Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.
Valuation History
Price per Share History
Note: Share prices shown in earlier rounds may not be indicative of any stock splits.